We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Bristol Myers Squibb (BMY) Stock Moves -0.26%: What You Should Know
Read MoreHide Full Article
Bristol Myers Squibb (BMY - Free Report) closed the most recent trading day at $75.98, moving -0.26% from the previous trading session. This change was narrower than the S&P 500's 2.38% loss on the day. Meanwhile, the Dow lost 1.94%, and the Nasdaq, a tech-heavy index, lost 0.64%.
Prior to today's trading, shares of the biopharmaceutical company had gained 0.04% over the past month. This has lagged the Medical sector's gain of 1.41% and outpaced the S&P 500's loss of 0.07% in that time.
Bristol Myers Squibb will be looking to display strength as it nears its next earnings release, which is expected to be July 27, 2022. On that day, Bristol Myers Squibb is projected to report earnings of $1.91 per share, which would represent a year-over-year decline of 1.04%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $11.52 billion, down 1.55% from the year-ago period.
BMY's full-year Zacks Consensus Estimates are calling for earnings of $7.59 per share and revenue of $46.33 billion. These results would represent year-over-year changes of +1.07% and -0.12%, respectively.
Any recent changes to analyst estimates for Bristol Myers Squibb should also be noted by investors. These revisions help to show the ever-changing nature of near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. The Zacks Consensus EPS estimate has moved 0.31% lower within the past month. Bristol Myers Squibb is holding a Zacks Rank of #3 (Hold) right now.
In terms of valuation, Bristol Myers Squibb is currently trading at a Forward P/E ratio of 10.03. This represents a discount compared to its industry's average Forward P/E of 21.92.
Investors should also note that BMY has a PEG ratio of 1.61 right now. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. BMY's industry had an average PEG ratio of 1.15 as of yesterday's close.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 105, which puts it in the top 42% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow BMY in the coming trading sessions, be sure to utilize Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Bristol Myers Squibb (BMY) Stock Moves -0.26%: What You Should Know
Bristol Myers Squibb (BMY - Free Report) closed the most recent trading day at $75.98, moving -0.26% from the previous trading session. This change was narrower than the S&P 500's 2.38% loss on the day. Meanwhile, the Dow lost 1.94%, and the Nasdaq, a tech-heavy index, lost 0.64%.
Prior to today's trading, shares of the biopharmaceutical company had gained 0.04% over the past month. This has lagged the Medical sector's gain of 1.41% and outpaced the S&P 500's loss of 0.07% in that time.
Bristol Myers Squibb will be looking to display strength as it nears its next earnings release, which is expected to be July 27, 2022. On that day, Bristol Myers Squibb is projected to report earnings of $1.91 per share, which would represent a year-over-year decline of 1.04%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $11.52 billion, down 1.55% from the year-ago period.
BMY's full-year Zacks Consensus Estimates are calling for earnings of $7.59 per share and revenue of $46.33 billion. These results would represent year-over-year changes of +1.07% and -0.12%, respectively.
Any recent changes to analyst estimates for Bristol Myers Squibb should also be noted by investors. These revisions help to show the ever-changing nature of near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. The Zacks Consensus EPS estimate has moved 0.31% lower within the past month. Bristol Myers Squibb is holding a Zacks Rank of #3 (Hold) right now.
In terms of valuation, Bristol Myers Squibb is currently trading at a Forward P/E ratio of 10.03. This represents a discount compared to its industry's average Forward P/E of 21.92.
Investors should also note that BMY has a PEG ratio of 1.61 right now. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. BMY's industry had an average PEG ratio of 1.15 as of yesterday's close.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 105, which puts it in the top 42% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow BMY in the coming trading sessions, be sure to utilize Zacks.com.